ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06747845

Title field or adapter rule

{'original_value': 'ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.674121+00:00

Published At

2026-10-13T00:00:00+00:00

Record Updated At

2026-10-13

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Adenocarcinoma Metastatic"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-13", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06747845"

protocolSection.identificationModule.officialTitle

"ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Adenocarcinoma Metastatic (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Niraparib + Ipilimumab (Arm A)'], 'description': 'Niraparib 200mg PO daily on days 1-21 of each 21-day cycle.', 'name': 'Niraparib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['FOLFIRI (Arm B)'], 'description': 'Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.', 'name': 'FOLFIRI', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Niraparib + Ipilimumab (Arm A)'], 'description': 'Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.', 'name': 'Ipilimumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Niraparib (protocolSection.armsInterventionsModule.interventions[].name)
• FOLFIRI (protocolSection.armsInterventionsModule.interventions[].name)
• Ipilimumab (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.